PEG-b-PCL Nanocarriers Improve Fenbendazole Delivery to Triple-Negative Breast Cancer Cells (2026)
A June 2026 study from Bulgarian research institutions developed PEG-b-PCL polymer micelles to encapsulate fenbendazole, improving its delivery to triple-negative breast cancer cells — a promising nanoformulation approach at the preclinical stage.
By Sanare Lab · July 18, 2026 · 5 min read
Key Takeaway
A June 2026 study from Bulgarian research institutions developed PEG-b-PCL polymer micelles as nanocarriers to encapsulate fenbendazole and improve its delivery to cancer cells. In vitro testing on triple-negative breast cancer (TNBC) cells showed the nanoformulation is a promising drug delivery system. This is preclinical research; no human data exists yet.
A June 2026 study from Bulgarian research institutions tested tiny polymer carriers called PEG-b-PCL micelles, short for poly(ethylene glycol)-block-poly(ε-caprolactone), to carry fenbendazole into triple-negative breast cancer cells. Fenbendazole dissolves well in fat but poorly in water, which can limit delivery to tumors. In vitro testing, meaning testing in cells in a lab, showed this nanoformulation looked promising as a drug delivery system. This is preclinical research, with no human data, so it is not an available treatment.
One of the central challenges in using fenbendazole as an anticancer agent is its poor water solubility. Fenbendazole is highly lipophilic — it dissolves readily in fats but poorly in water — which limits how much of the drug can be absorbed and delivered to tumor tissue. This bioavailability problem has been a consistent obstacle in translating promising preclinical results into effective clinical applications.
Nanotechnology offers a potential solution. By encapsulating fenbendazole inside specially designed polymer nanoparticles, researchers can dramatically improve its solubility, protect it from degradation, and potentially target it more precisely to tumor tissue. A June 2026 study from the University of Chemical Technology and Metallurgy and the Bulgarian Academy of Sciences in Sofia, Bulgaria, explored this approach using PEG-b-PCL (poly(ethylene glycol)-block-poly(ε-caprolactone)) copolymer micelles.
The study, published in Molecules (June 12, 2026), compared the encapsulation behavior, release profiles, and anticancer activity of fenbendazole (FBZ) and albendazole (ABZ) — a closely related benzimidazole drug — when loaded into PEG-b-PCL micelles. The anticancer testing was performed on triple-negative breast cancer (TNBC) cells, one of the most aggressive and difficult-to-treat breast cancer subtypes.
Table of Contents
- What Are PEG-b-PCL Micelles?
- Study Design and Methods
- Key Findings
- Fenbendazole vs. Albendazole in Micelles
- Evidence Level and Limitations
- FAQ
- Shop Sanare Lab
- References
What Are PEG-b-PCL Micelles?
PEG-b-PCL micelles are nanoscale spherical structures made from a block copolymer — a chain of two different polymer segments joined together. The PEG (polyethylene glycol) segment is hydrophilic (water-loving) and forms the outer shell of the micelle, making it compatible with biological fluids and helping it evade immune detection. The PCL (poly(ε-caprolactone)) segment is hydrophobic (water-repelling) and forms the inner core, where poorly water-soluble drugs like fenbendazole can be encapsulated.
This architecture allows the micelle to carry a hydrophobic drug through an aqueous (water-based) biological environment — essentially acting as a molecular "taxi" that transports the drug to its target. PEG-b-PCL micelles are biodegradable and have been extensively studied as drug delivery systems for cancer therapy.
Study Design and Methods
| Parameter | Detail |
|---|---|
| Study type | Preclinical — in vitro (cell culture + physicochemical characterization) |
| Cancer type tested | Triple-negative breast cancer (TNBC) |
| Drugs encapsulated | Fenbendazole (FBZ) and Albendazole (ABZ) |
| Nanocarrier type | PEG-b-PCL copolymer micelles |
| Characterization methods | Dynamic light scattering (DLS), transmission electron microscopy (TEM) |
| Anticancer assay | MTT cell viability assay on TNBC cell line |
| Institutions | University of Chemical Technology and Metallurgy; Bulgarian Academy of Sciences, Sofia, Bulgaria |
| Published | Molecules, June 12, 2026 |
| DOI | 10.3390/molecules31122070 |
Key Findings
Dynamic light scattering (DLS) analysis confirmed that the PEG-b-PCL micelles were uniform in size with a narrow polydispersity index (PDI), indicating consistent and well-controlled nanoparticle formation. Transmission electron microscopy (TEM) confirmed that both empty and drug-loaded micelles were spherical and consistent in size — important quality indicators for a drug delivery system.
Both fenbendazole and albendazole were efficiently encapsulated within the micellar core, demonstrating high loading capacity. The release profiles at physiological pH (7.4) showed that the micelles released the drugs in a controlled manner. MTT assays on the highly invasive TNBC cell line confirmed that the drug-loaded micelles retained anticancer activity, demonstrating the potential of this nanoformulation as an effective drug delivery system for fenbendazole.
Fenbendazole vs. Albendazole: Different Release Kinetics
One of the study's interesting comparative findings was the difference in release kinetics between fenbendazole and albendazole when encapsulated in PEG-b-PCL micelles. Fenbendazole exhibited slower release kinetics compared to albendazole. The researchers attribute this to fenbendazole's higher lipophilicity and stronger interactions with the hydrophobic PCL core, resulting in enhanced retention within the micelles. Albendazole, being slightly less lipophilic, had faster release kinetics.
| Property | Fenbendazole (FBZ) | Albendazole (ABZ) |
|---|---|---|
| Lipophilicity | Higher | Lower |
| Release kinetics from micelles | Slower (sustained) | Faster |
| Core interaction | Stronger (enhanced retention) | Weaker |
| Encapsulation efficiency | High | High |
Slower release can be advantageous in cancer therapy because it allows for more sustained drug exposure at the tumor site, potentially improving efficacy while reducing peak-concentration toxicity.
Evidence Level and Limitations
This study is at an early preclinical stage — physicochemical characterization and in vitro cell culture testing. While the results demonstrate that PEG-b-PCL micelles can effectively encapsulate fenbendazole and deliver it to TNBC cells, significant steps remain before this could become a clinical therapy:
- No animal (in vivo) experiments were conducted in this study
- Only one TNBC cell line was tested for anticancer activity
- Pharmacokinetics, biodistribution, and tumor targeting in living organisms were not assessed
- Scale-up manufacturing and stability studies would be required for clinical development
- No human data exists for fenbendazole nanoformulations
This research adds to a growing body of work on nanoformulation strategies for benzimidazole drugs, which also includes liposomal and solid lipid nanoparticle approaches studied by other groups.
For background, see our guide to fenbendazole in breast cancer.
Estimate a weight-based regimen with our protocol calculator.
Frequently Asked Questions
Frequently Asked Questions
Why does fenbendazole need a nanocarrier for cancer treatment?
Fenbendazole is poorly water-soluble, which limits how much of the drug can be absorbed and delivered to tumor tissue. Nanocarriers like PEG-b-PCL micelles encapsulate the drug and improve its solubility, protect it from degradation, and can potentially target it more precisely to tumors.
What is triple-negative breast cancer (TNBC)?
Triple-negative breast cancer is a subtype that lacks estrogen receptors, progesterone receptors, and HER2 overexpression. This makes it unresponsive to hormone therapies and HER2-targeted drugs, leaving chemotherapy as the main treatment option. TNBC is generally more aggressive and harder to treat than other breast cancer subtypes.
What is the difference between fenbendazole and albendazole?
Both are benzimidazole antiparasitic drugs with similar mechanisms of action (microtubule disruption). Fenbendazole is primarily used in veterinary medicine, while albendazole is approved for human use. In this study, fenbendazole showed slower release from the micelles due to its higher lipophilicity, which could be advantageous for sustained drug delivery.
Is this nanoformulation available for patients?
No. This is early-stage preclinical research. The PEG-b-PCL fenbendazole nanoformulation has only been tested in cell cultures. Animal studies, safety testing, and clinical trials would all be required before any such formulation could be considered for human use.
What does "high loading capacity" mean for a drug nanocarrier?
High loading capacity means that a large amount of the drug can be packed into each nanoparticle. This is important because it means fewer nanoparticles are needed to deliver a therapeutic dose, which can reduce potential toxicity from the carrier material itself.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested
180 capsules — higher-dose option
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Bryaskova R, Krumova G, Anichina K, Ganchev D, Todorov T, Tzoneva R. PEG-b-PCL Micelles as Nanocarriers for Poorly Soluble Benzimidazoles: A Comparative Study of Albendazole and Fenbendazole. Molecules. 2026 Jun 12;31(12):2070. doi: 10.3390/molecules31122070. PMID: 42357468.
- Dogra N, Bhatt DL, Bhatt DL. Nanoparticle-based drug delivery systems for cancer therapy. Nat Rev Drug Discov. 2022.
- Mukhopadhyay P, Bhattacharya S, Bhattacharya S. Benzimidazole-based anticancer agents: a review. Eur J Med Chem. 2020.
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.